VC
CRVS icon

Vivo Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Vivo Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.9M Hold
2,805,816
– – 3.83% 7
2026
Q1 		$41M Buy
2,805,816
+571,250
+26% +$9.12M 3.41% 9
2025
Q4 		$17.2M Hold
2,234,566
– – 1.11% 26
2025
Q3 		$16.5M Hold
2,234,566
– – 1.33% 24
2025
Q2 		$8.94M Hold
2,234,566
– – 0.91% 22
2025
Q1 		$7.11M Hold
2,234,566
– – 0.94% 23
2024
Q4 		$12M Buy
2,234,566
+737,298
+49% +$5.5M 1.34% 17
2024
Q3 		$7.91M Buy
+1,497,268
New +$5.38M 0.65% 25

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vivo Capital's CRVS Position: Q2 2026 in Review

Vivo Capital held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 2,805,816 shares worth $41.9M. The position accounts for 3.83% of the portfolio, ranked #7.

Vivo Capital first reported a position in CRVS in Q3 2024 and has held it in 8 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Vivo Capital held 2,805,816 shares of Corvus Pharmaceuticals worth $41.9M as of Q2 2026.
  • Vivo Capital left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
  • Corvus Pharmaceuticals made up 3.83% of Vivo Capital's portfolio in Q2 2026, its #7 holding.
  • Vivo Capital first reported a position in Corvus Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.